Skip to content

Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients

A Single-center Prospective Measurement of Adherence to Treatment With Tecfidera™ in Multiple Sclerosis Patients.

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02099370
Acronym
ADIMS
Enrollment
34
Registered
2014-03-28
Start date
2014-03-31
Completion date
2016-01-31
Last updated
2020-04-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Multiple Sclerosis

Keywords

Multiple Sclerosis, Tecfidera(R), Oral medication, Adherence

Brief summary

The investigators are measuring the adherence rates of an oral MS drug that is to be administered twice-daily. The investigators would like to observe any patterns that might indicate factors that greatly affect adherence.

Interventions

None listed

Sponsors

Biogen
CollaboratorINDUSTRY
University of South Florida
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Must give written informed consent and any authorizations required by local law (e.g., Protected Health Information \[PHI\]). * Aged 18 at the time of informed consent. * Must have a relapsing form of MS. * Male subjects and female subjects of child-bearing potential (including female subjects who are not post-menopausal for at least 1 year) must be willing to practice effective contraception (as defined by the investigator) during the study and be willing and able to continue contraception for 30 days after their last dose of study treatment.

Exclusion criteria

* Progressive form of MS * History of severe allergic or anaphylactic reactions or known drug hypersensitivity. * Female subjects considering becoming pregnant while in the study. * Female subjects who are currently pregnant or breast-feeding. * Unwillingness or inability to comply with the requirements of the protocol including the presence of any conditional (physical, mental or social) that is likely to affect the subject's ability to comply with the protocol. * Any other reason that, in opinion of the Investigator and/or the Sponsor, the subject is determined to be unsuitable for enrollment in this study.

Design outcomes

Primary

MeasureTime frame
adherence rates to Tecfideraover one year

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026